In breast cancer, one study reported that ATG4B inhibited growth of triple-negative breast cancer cell lines and a candidate agonist of ATG4B, Flubendazole, displayed anti-proliferative effects34. This evidence concerns the gene ATG4B and triple-negative breast carcinoma.